Memory response against Bordetella pertussis in adults: immunological effects of an acellular pertussis booster vaccination - VIKING-study

ational Institute for Public Health and the Environment (RIVM, the Netherlands)0 个研究点目标入组 100 人开始时间: 2014年2月24日最近更新: 2020年5月11日

适应症

试验速览

暂无简介。

•In order to be eligible to participate in this study, participants must meet all of the following criteria:
•Good general health;
•25-29 years of age;
•Vaccinated with DTwP-IPV (RIVM) at 3, 4, 5, and 11 months of age;
•Received all other regular vaccines according to the Dutch NIP;
•Provision of written informed consent;
•Adherent to protocol and available during the study period.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 100
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Any of the following criteria will exclude a participant from this study:
•Antibiotic use within 14 days of enrollment;
•Present evidence of serious disease(s) demanding immunosuppressive medical treatment, like corticosteroids, that might interfere with the results of the study within the last 3 months;
•Known or suspected allergy to any of the vaccine components (by medical history);
•Occurrence of serious adverse event after primary DTwP-IPV vaccination or other vaccination (by medical history);
•Known or suspected immune deficiency;
•History of any neurologic disorder, including epilepsy;
•Previous administration of serum products (including immunoglobulins) within 6 months before vaccination and blood/ saliva sampling;
•Vaccination with any other pertussis vaccine than those described in the inclusion criteria;
•No DT or DT-IPV vaccination at least 5 years before enrollment;
•Vaccination within a month before enrollment;
•Pregnant at start of study (when vaccination is administered);

发起方

ational Institute for Public Health and the Environment (RIVM, the Netherlands)